Trials / Active Not Recruiting
Active Not RecruitingNCT05255159
Lesion-to-lesion Comparison of 68Ga-HA-DOTATATE, 18F-DOPA, and 18F-FDG PET/CT in the Evaluation of Metastatic Neuroendocrine Tumors
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- University of Alberta · Academic / Other
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
This study is a single centre non-randomized non-blinded phase II prospective cohort study including 50 participants. The objective of this study is to directly compare 68Ga-HA-DOTATATE, 18F-DOPA, and 18F-FDG activity in patients with metastatic neuroendocrine tumors (NETs) on a lesion-by-lesion basis. The investigators will determine the prevalence of concordant versus discordant disease. Secondary objectives include assessing the standardized uptake value (SUV) and determining if there is any correlation between discordance and disease progression.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | 18F-DOPA with furosemide | Diagnostic 18F-DOPA PET/CT scan |
Timeline
- Start date
- 2022-10-15
- Primary completion
- 2025-06-30
- Completion
- 2026-06-30
- First posted
- 2022-02-24
- Last updated
- 2025-11-17
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT05255159. Inclusion in this directory is not an endorsement.